The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
11.06.2015
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
11.06.2015
Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph
Weiter
